Prot# SPR001-203: A Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia"

Project: Research project

Project Details

StatusFinished
Effective start/end date8/25/21 → 12/31/24

Funding

  • Medpace Clinical Research LLC (Prot# SPR001-203 // Prot# SPR001-203)
  • Spruce Biosciences, Inc. (Prot# SPR001-203 // Prot# SPR001-203)